alexa Colon Cancer and Immunotherapy: CD40 Ligand as a Potent
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review

Colon Cancer and Immunotherapy: CD40 Ligand as a Potential Therapeutic Target

Orfanos S1, Patelis N1*, Davakis S1, Vailas M1, Damaskos C2, Margonis GA3, Pikoulis E1 and Antoniou E2

1First Department of Surgery, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece

2Department of Propaedeutic Surgery, Laiko General Hospital, School of Medicine, University of Athens, Athens, Greece

3Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore

*Corresponding Author:
Dr. Nikolaos Patelis
First Department of Surgery
Laiko General Hospital
National and Kapodistrian University of Athens
Athens, Greece
Tel: 302107456243
E-mail: [email protected]

Received Date: February 23, 2017 Accepted Date: March 14, 2017 Published Date: March 17, 2017

Citation: Orfanos S, Patelis N, Davakis S, Vailas M, Damaskos C, et al. (2017) Colon Cancer and Immunotherapy: CD40 Ligand as a Potential Therapeutic Target. J Mol Genet Med 11: 253 doi:10.4172/1747-0862.1000253

Copyright: © 2017 Orfanos S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited



CD40, a member of the tumor necrosis factor (TNF) superfamily, it is broadly expressed on a variety of cells. There are studies to suggest that the expression of CD40 is correlated to several malignancies, while its innate therapeutic qualities are yet to be confirmed. Colon cancer is one of the most common cancers, while little can be done for the patients with advance colon cancer even at the presence time. CD40 are present in the colon cancer, and are a possible therapeutic immunotherapy target in order to enhance the overall survival rates of the patients with advanced disease.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version